Ionis (IONS) Stock Price Target Cut to $95 After Trial Results
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowCanaccord has reduced its price target for Ionis Pharmaceuticals (IONS) to $95 following the company's trial misses. The revision reflects concerns regarding Ionis's pipeline and potential future earnings performance. This adjustment may influence investor perception and stock performance, especially as the markets react to updated forecasts. Such price target changes can indicate underlying issues that affect stock valuation and investor sentiment.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
